Sign in

CIK 0001880438 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

AN2 Therapeutics, Inc.

Sign in to watch
Ticker
ANTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
820606654
Phone
(650) 331-9090
Business address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
Open-market buys, last 90 days
$11,602
in 1 filing
Open-market sales, last 90 days
$117,428
in 4 filings, $104K under 10b5-1 plans

Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 94 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-07-08 Eizen Joshua M See Remarks Sale −5,945 $4.17 $25K 206,554
2026-05-29 Williams Sarah Joanne Principal Accounting Officer Sale −265 $4.43 $1K 66,583
2026-04-10 Aziz Kabeer Director Grant or award +3,775 56,254
2026-04-10 Marks Gilbert Lynn Director Grant or award +3,775 79,084
2026-04-10 Martin Patricia A. Director Grant or award +1,192 18,097
2026-03-19 Day Lucy Chief Financial Officer Grant or award · Stock Option (right to buy) +73,665 73,665
2026-03-19 Day Lucy Chief Financial Officer Returned to the company · Stock Option (right to buy) −73,665 0
2026-03-19 Day Lucy Chief Financial Officer Grant or award · Stock Option (right to buy) +66,000 66,000
2026-03-19 Day Lucy Chief Financial Officer Returned to the company · Stock Option (right to buy) −66,000 0
2026-03-19 Day Lucy Chief Financial Officer Grant or award · Stock Option (right to buy) +82,300 82,300
2026-03-19 Day Lucy Chief Financial Officer Returned to the company · Stock Option (right to buy) −82,300 0
2026-03-19 Chanda Sanjay Chief Development Officer Grant or award · Stock Option (right to buy) +66,000 66,000
2026-03-19 Chanda Sanjay Chief Development Officer Returned to the company · Stock Option (right to buy) −66,000 0
2026-03-19 Chanda Sanjay Chief Development Officer Grant or award · Stock Option (right to buy) +57,950 57,950
2026-03-19 Chanda Sanjay Chief Development Officer Returned to the company · Stock Option (right to buy) −57,950 0
2026-03-19 Chanda Sanjay Chief Development Officer Grant or award · Stock Option (right to buy) +41,665 41,665
2026-03-19 Chanda Sanjay Chief Development Officer Returned to the company · Stock Option (right to buy) −41,665 0
2026-03-19 Marks Gilbert Lynn Director Grant or award · Stock Option (right to buy) +10,665 10,665
2026-03-19 Marks Gilbert Lynn Director Returned to the company · Stock Option (right to buy) −10,665 0
2026-03-19 Marks Gilbert Lynn Director Grant or award · Stock Option (right to buy) +10,362 10,362

Page 2 of 10 · 191 trades